MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
BioNano Genomics Operating Income 2011-2026 | BNGO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -33.3 M | -104 M | -215 M | -132 M | -77.1 M | -38.6 M | -25.9 M | -20.4 M | -23.2 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.4 M | -215 M | -74.4 M |
Quarterly Operating Income BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.54 M | -7.8 M | -8.46 M | - | -43.9 M | -17 M | -31.1 M | - | -113 M | -39.2 M | -37.8 M | - | -32.1 M | -32.1 M | -29.9 M | - | -20.7 M | -16.5 M | -11.2 M | - | -10.2 M | -7.44 M | -9.76 M | - | -5.68 M | -6.84 M | -6.18 M | - | -5.97 M | -4.01 M | -4.34 M | - | -5.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.01 M | -113 M | -20.6 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
54 M | $ 9.19 | 2.06 % | $ 612 M |  USA |
|
Biodesix
BDSX
|
-34.5 M | $ 15.31 | 4.22 % | $ 1.99 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
311 M | $ 74.11 | -2.15 % | $ 5 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 463.46 | 1.43 % | $ 13.4 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 159.84 | 1.16 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 165.65 | -0.81 % | $ 28.5 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.67 | 0.11 % | $ 432 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.26 | -1.46 % | $ 386 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 125.17 | 1.11 % | $ 19.9 B | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
-7.62 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 101.12 | -5.27 % | $ 3.99 B | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.67 | 0.72 % | $ 454 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 266.56 | 0.81 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
RadNet
RDNT
|
62 M | $ 59.22 | -4.09 % | $ 4.45 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.87 | -2.82 % | $ 1.01 B | USA |
 |
Natera
NTRA
|
-541 M | $ 193.75 | -3.17 % | $ 19.1 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 6.63 | 0.08 % | $ 277 M | USA |
 |
Sotera Health Company
SHC
|
248 M | $ 13.82 | -0.43 % | $ 3.92 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.65 | 0.51 % | $ 941 M | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 30.84 | -2.77 % | $ 1.57 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.23 | -2.02 % | $ 701 M | USA |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 8.05 | 7.27 % | $ 32.1 M | Israel |
 |
DexCom
DXCM
|
912 M | $ 66.28 | 0.51 % | $ 25.9 B | USA |
 |
Neuronetics
STIM
|
-31.4 M | $ 1.47 | -8.12 % | $ 96.9 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 104.91 | - | $ 19.8 B | USA |